{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:48:03Z","timestamp":1774432083876,"version":"3.50.1"},"posted":{"date-parts":[[2025,6,3]]},"group-title":"In Review","reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,19]]},"abstract":"<title>Abstract<\/title>\n                <p>Accurate prediction of risk of progression from smoldering (SMM) to active multiple myeloma (MM) is paramount to individualized early therapeutic strategies with minimum risk of overtreatment. Current risk stratification models do not account for evolving biomarker trajectories. We assembled the largest cohort to date of 2,270 SMM patients from six international centers with longitudinal clinical and biological data to train and validate the PANGEA 2.0 risk models. Four evolving biomarkers were significantly associated with shorter time-to-progression: M-protein increase \u22650.2g\/dL, involved:uninvolved serum free light chain ratio increase \u226520, creatinine increase &gt;25%, and hemoglobin decrease \u22651.5g\/dL. PANGEA 2.0 outperforms established models including the 20\/2\/20 and IMWG models by more accurately predicting progression (C-statistics=0.69\u20130.84), even without biomarker history (C-statistics=0.69\u20130.83) or recent bone marrow biopsy. PANGEA 2.0 is an easy-to-use, open-access tool (https:\/\/ghobrial.shinyapps.io\/pangea_2_calculator) to improve and individualize SMM risk stratification. Validation tools are available to compare PANGEA 2.0 to established models (https:\/\/ghobrial.shinyapps.io\/pangea_validation).<\/p>","DOI":"10.21203\/rs.3.rs-6696313\/v1","type":"posted-content","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T09:31:02Z","timestamp":1748943062000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-8711","authenticated-orcid":false,"given":"Floris","family":"Chabrun","sequence":"first","affiliation":[{"name":"Angers University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Gentile","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias","family":"Mai","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulika","family":"Gupta","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Perry","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-8338","authenticated-orcid":false,"given":"David Cordas Dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[{"name":"German Cancer Research Center (DKFZ)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Werly","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital and Medical Faculty Heidelberg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital and Medical Faculty Heidelberg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Liacos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Cancer Center Clinica Universidad de Navarra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Martin-Sanchez","sequence":"additional","affiliation":[{"name":"Cancer Center Clinica Universidad de Navarra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalinda","family":"Termini","sequence":"additional","affiliation":[{"name":"Cancer Center Clinica Universidad de Navarra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[{"name":"University Hospital Wuerzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Chavda","sequence":"additional","affiliation":[{"name":"University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Ainley","sequence":"additional","affiliation":[{"name":"University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Claudio Da","family":"Vi\u00e0","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"de Magistris","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Pettine","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-3502","authenticated-orcid":false,"given":"Michael","family":"Timonian","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute of MIT & Harvard"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhi","family":"Patel","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Costello","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Tobia","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Phan","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Lamb","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Theresa","family":"Silverio","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Davis","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Marinac","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-5139","authenticated-orcid":false,"given":"Niccolo","family":"Bolli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-276X","authenticated-orcid":false,"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria Victoria Mateos","family":"Manteca","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBASL), Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC-USAL,CSIC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus San","family":"Miguel","sequence":"additional","affiliation":[{"name":"University of Navarra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"Cancer Center Cl\u00ednica Universidad de Navarra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathis","family":"Kastritis","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc","family":"Raab","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital, German Cancer Research Center (DKFZ)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e538-48","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-48, 2014.","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman A","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, et al: Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 8:59, 2018.","journal-title":"Blood Cancer J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, et al: International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 10:102, 2020.","journal-title":"Blood Cancer J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi P","year":"2016","unstructured":"Ravi P, Kumar S, Larsen JT, et al: Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 6:e454, 2016.","journal-title":"Blood Cancer J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea C","year":"2018","unstructured":"Fern\u00e1ndez de Larrea C, Isola I, Pereira A, et al: Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 32:1427\u201334, 2018.","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1002\/hem3.76","article-title":"The evolving pattern of the monoclonal protein improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma","volume":"8","author":"Daniel A","year":"2024","unstructured":"de Daniel A, Rodr\u00edguez-Lobato LG, Tovar N, et al: The evolving pattern of the monoclonal protein improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma. Hemasphere 8:e76, 2024.","journal-title":"Hemasphere"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","author":"Blad\u00e9 J","year":"2010","unstructured":"Blad\u00e9 J, Dimopoulos M, Rosi\u00f1ol L, et al: Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28:690\u20137, 2010.","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-018-0144-x","article-title":"Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma","volume":"8","author":"Atrash S","year":"2018","unstructured":"Atrash S, Robinson M, Slaughter D, et al: Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J 8:107, 2018.","journal-title":"Blood Cancer J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"E63-E65","DOI":"10.1002\/ajh.26062","article-title":"Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression","volume":"96","author":"Gran C","year":"2021","unstructured":"Gran C, Luong V, Bruchfeld JB, et al: Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. Am J Hematol 96:E63-E65, 2021.","journal-title":"Am J Hematol"},{"key":"ref10","author":"Akhlaghi T","year":"2023","unstructured":"Akhlaghi T: Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma, in ASH, 2023."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosi\u00f1ol L","year":"2003","unstructured":"Rosi\u00f1ol L, Blad\u00e9 J, Esteve J, et al: Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 123:631\u20136, 2003.","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu V","year":"2018","unstructured":"Wu V, Moshier E, Leng S, et al: Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2:1470\u20139, 2018.","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e302-e312","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass J","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, et al: International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302-e312, 2019.","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","article-title":"Mode of progression in smoldering multiple myeloma: a study of 406 patients","volume":"14","author":"Abdallah NH","year":"2024","unstructured":"Abdallah NH, Lakshman A, Kumar SK, et al: Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J 14:9, 2024.","journal-title":"Blood Cancer J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41408-024-01159-8","article-title":"Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma","volume":"14","author":"Werly A","year":"2024","unstructured":"Werly A, Hampel M, Hielscher T, et al: Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma. Blood Cancer J 14:176, 2024.","journal-title":"Blood Cancer J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","article-title":"New horizons in our understanding of precursor multiple myeloma and early interception","volume":"24","author":"Cordas Dos Santos DM","year":"2024","unstructured":"Cordas Dos Santos DM, Toenges R, Bertamini L, et al: New horizons in our understanding of precursor multiple myeloma and early interception. Nat Rev Cancer 24:867\u201386, 2024.","journal-title":"Nat Rev Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.2024023880","article-title":"Smoldering multiple myeloma: taking the narrow over the wide path","volume":"143","author":"Avet-Loiseau H","year":"2024","unstructured":"Avet-Loiseau H, Bahlis NJ: Smoldering multiple myeloma: taking the narrow over the wide path. Blood 143:2025\u20138, 2024.","journal-title":"Blood"},{"key":"ref18","author":"Dimopoulos M-A","unstructured":"Dimopoulos M-A: Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study [Internet], in ASH, 2024 [cited 2024 Dec 28] Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper201057.html"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.2024025897","article-title":"Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS","volume":"145","author":"Landgren O","year":"2025","unstructured":"Landgren O, Chari A, Cohen YC, et al: Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood 145:1658\u201369, 2025.","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos MV","year":"2016","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P, et al: Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 17:1127\u201336, 2016.","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","author":"Lonial S","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, et al: Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 38:1126\u201337, 2020.","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-021-00569-2","article-title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","volume":"11","author":"Visram A","year":"2021","unstructured":"Visram A, Rajkumar SV, Kapoor P, et al: Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J 11:186, 2021.","journal-title":"Blood Cancer J"},{"key":"ref23","volume-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations","author":"Avet-Loiseau H","unstructured":"Avet-Loiseau H, et al: International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"TPS8075","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8075","article-title":"Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study","volume":"40","author":"Dimopoulos MA","year":"2022","unstructured":"Dimopoulos MA, Voorhees PM, Goldschmidt H, et al: Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study. JCO 40:TPS8075\u2013TPS8075, 2022.","journal-title":"JCO"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma","volume":"142","author":"Nadeem O","year":"2023","unstructured":"Nadeem O, Magidson S, Midha S, et al: Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma. Blood 142:206, 2023.","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren CO","year":"2020","unstructured":"Landgren CO, Chari A, Cohen YC, et al: Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 34:1840\u201352, 2020.","journal-title":"Leukemia"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1002\/hem3.61","article-title":"Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma","volume":"8","author":"Mellgard G","year":"2024","unstructured":"Mellgard G, Gilligan M, Cliff ERS, et al: Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere 8:e61, 2024.","journal-title":"Hemasphere"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e203-e212","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan A","year":"2023","unstructured":"Cowan A, Ferrari F, Freeman SS, et al: Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol 10:e203-e212, 2023.","journal-title":"Lancet Haematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1182\/blood-2019-132260","article-title":"Update on Risk Stratification Model of Smoldering Multiple Myeloma: A Systematic Review","volume":"134","author":"Malik SU","year":"2019","unstructured":"Malik SU, Abu-Hashyeh A, Sardar M, et al: Update on Risk Stratification Model of Smoldering Multiple Myeloma: A Systematic Review. Blood 134:5512, 2019.","journal-title":"Blood"},{"key":"ref30","first-page":"2736","article-title":"Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management","volume":"11","author":"Vasco-Mogorr\u00f3n MA","year":"2021","unstructured":"Vasco-Mogorr\u00f3n MA, Campillo JA, Periago A, et al: Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am J Cancer Res 11:2736\u20132753, 2021.","journal-title":"Am J Cancer Res"},{"key":"ref31","author":"Therneau TM","year":"2024","unstructured":"Therneau TM: A Package for Survival Analysis in R, 2024."},{"key":"ref32","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2022."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/j.arth.2021.04.015","article-title":"Competing Risk Analysis: What Does It Mean and When Do We Need It in Orthopedics Research","volume":"36","author":"Maradit Kremers H","year":"2021","unstructured":"Maradit Kremers H, Devick KL, Larson DR, et al: Competing Risk Analysis: What Does It Mean and When Do We Need It in Orthopedics Research. J Arthroplasty 36:3362\u20136, 2021.","journal-title":"J Arthroplasty"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/0272989X18801312","article-title":"A Tutorial on Evaluating the Time-Varying Discrimination Accuracy of Survival Models Used in Dynamic Decision Making","volume":"38","author":"Bansal A","year":"2018","unstructured":"Bansal A, Heagerty PJ: A Tutorial on Evaluating the Time-Varying Discrimination Accuracy of Survival Models Used in Dynamic Decision Making. Med Decis Making 38:904\u201316, 2018.","journal-title":"Med Decis Making"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche P","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H: Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32:5381\u201397, 2013.","journal-title":"Stat Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","article-title":"Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice","volume":"5","author":"Trevethan R","year":"2017","unstructured":"Trevethan R: Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health 5:307, 2017.","journal-title":"Front Public Health"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6696313\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6696313\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:13:27Z","timestamp":1774422807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6696313\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":36,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6696313\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41591-026-04304-x","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,6,3]]},"subtype":"preprint"}}